🇺🇸 FDA
Patent

US 7425611

Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use

granted A61KA61K2039/53A61K2039/57

Quick answer

US patent 7425611 (Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use) held by The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention expires Mon Sep 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Grant date
Tue Sep 16 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/53, A61K2039/57, A61K2039/645, A61K39/00